[Prolonged interferon papillomavirus infection treatment]

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Recurrent genital human papillomavirus (HPV) infections, particularly types 6 and 11, pose a significant clinical challenge.
• Current short-term treatment regimens may not fully eradicate the virus or restore immune balance, leading to frequent recurrences.

Purpose of the Study:

• To evaluate the efficacy of a prolonged treatment scheme with genferon suppositories compared to a short scheme for recurrent HPV infections.
• To assess the impact of prolonged genferon use on immune and cytokine status and viral elimination.

Main Methods:

• Patients with recurrent genital HPV (types 6 and 11) were treated with either a prolonged genferon scheme (500,000 IU twice daily for 10 days, then twice weekly for 3 months) or a short scheme (500,000 IU twice daily for 10 days).
• Effectiveness was measured by recurrence prevention, immune and cytokine status normalization, and viral agent elimination.
• Safety and side effects were monitored throughout the study.

Main Results:

• The prolonged genferon treatment scheme demonstrated superior effectiveness in preventing HPV recurrence compared to the short scheme.
• Prolonged treatment led to normalization of immune and cytokine status and successful elimination of the human papillomavirus infectious agent from affected tissues.
• No undesirable side effects were observed with the prolonged administration of genferon suppositories.

Conclusions:

• A prolonged treatment regimen with genferon suppositories is a more effective strategy for managing recurrent genital HPV infections caused by types 6 and 11.
• The enhanced efficacy is attributed to the drug's pharmacological properties, which provide both systemic and local effects, leading to immune restoration and viral clearance.
• Extended genferon use offers a safe and effective approach to preventing HPV recurrence.